ABSTRACT
Trade names: Avelox (Bayer Schering), Moxeza (Alcon) Indications: Various infections caused by susceptible organisms Class: Antibiotic, fluoroquinolone Half-life: 12 hours Clinically important, potentially hazardous interactions with: alfuzosin, aminophylline, amiodarone, amitriptyline, antacids, arsenic, artemether / lumefantrine, asenapine, atomoxetine, BCG vaccine, benperidol, bepridil, bretylium, chloroquine, ciprofloxacin, corticosteroids, cyclosporine, degarelix, didanosine, disopyramide, dronedarone, droperidol, erythromycin, gadobutrol, haloperidol, hydroxychloroquine, insulin, lanthanum, levomepromazine, magnesium salts, mefloquine, mizolastine, mycophenolate, nilotinib, NSAIDs, oral iron, oral typhoid vaccine, pentamidine, phenothiazines, pimozide, probenecid, procainamide, QT prolonging agents, quinapril, quinidine, quinine, sevelamer, sotalol, strontium ranelate, sucralfate, sulfonylureas, tetrabenazine, thioridazine, tricyclic antidepressants, vandetanib, vitamin K antagonists, warfarin, zinc, ziprasidone, zolmitriptan, zuclopenthixol Pregnancy category: C Note: Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis. Moxeza is for topical ophthalmic use only.
